RARβ acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells.


Journal

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484

Informations de publication

Date de publication:
02 2019
Historique:
pubmed: 27 9 2018
medline: 1 10 2019
entrez: 26 9 2018
Statut: ppublish

Résumé

This study investigates the mechanism and consequences of microRNA-22 ( miR-22) induction. Our data revealed for the first time that retinoic acid (RA) and histone deacetylase (HDAC) inhibitors, including short-chain fatty acids and suberanilohydroxamic acid (SAHA), could individually or in combination induce miR-22. This induction was mediated via RA receptor β (RARβ) binding to a direct repeat 5 (DR5) motif. In addition, we uncovered HDAC1 as a novel miR-22 target. In an miR-22-dependent manner, HDAC inhibitors and RA reduced HDAC1, HDAC4, and sirtuin 1 (SIRT1), which were involved in chromatin remodeling of the RARβ and nerve growth factor IB ( NUR77). Thus, HDAC inhibitors and RA-induced miR-22 resulted in simultaneous induction of cytoplasmic RARβ and NUR77, leading to apoptosis of colon cancer cells. In mice, miR-22 and its inducers inhibited the growth of xenograft colon cancer. Moreover, tumor size reduction was accompanied by elevated miR-22, NUR77, and RARβ and by reduced HDACs. In human colon polyps and adenocarcinomas, miR-22 and RARβ were consistently reduced, which was associated with elevated HDAC1, HDAC4, and SIRT1 in colon adenocarcinomas. Results from this study revealed a novel anticancer mechanism of RARβ via miR-22 induction to epigenetically regulate itself and NUR77, providing a promising cancer treatment modality using miR-22 and its inducers.-Hu, Y., French, S. W., Chau, T., Liu, H.-X., Sheng, L., Wei, F., Stondell, J., Garcia, J. C., Du, Y., Bowlus, C. L., Wan, Y.-J. Y. RARβ acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells.

Identifiants

pubmed: 30252536
doi: 10.1096/fj.201801390R
pmc: PMC6338632
doi:

Substances chimiques

Histone Deacetylase Inhibitors 0
MIRN22 microRNA, human 0
MicroRNAs 0
NR4A1 protein, human 0
Nuclear Receptor Subfamily 4, Group A, Member 1 0
Receptors, Retinoic Acid 0
retinoic acid receptor beta 0
Tretinoin 5688UTC01R
HDAC1 protein, human EC 3.5.1.98
Histone Deacetylase 1 EC 3.5.1.98

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2314-2326

Subventions

Organisme : NCI NIH HHS
ID : R01 CA222490
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA179582
Pays : United States

Références

Int J Oncol. 2017 Feb;50(2):345-355
pubmed: 28000852
Proc Natl Acad Sci U S A. 2014 May 20;111(20):7421-6
pubmed: 24799697
Hum Mol Genet. 2012 May 15;21(10):2157-65
pubmed: 22328083
Proc Nutr Soc. 2008 May;67(2):115-27
pubmed: 18412986
Oncol Rep. 2015 Oct;34(4):1771-8
pubmed: 26239725
Carcinogenesis. 2012 Feb;33(2):301-11
pubmed: 22159226
Mol Cancer Res. 2015 Feb;13(2):281-92
pubmed: 25232032
FEBS J. 2010 Apr;277(7):1684-94
pubmed: 20180843
Genes Chromosomes Cancer. 2009 Jun;48(6):521-31
pubmed: 19306352
Exp Biol Med (Maywood). 2014 Nov;239(11):1489-504
pubmed: 24951470
Mol Cell Biol. 2003 Dec;23(23):8651-67
pubmed: 14612408
J Cell Physiol. 2011 Feb;226(2):322-30
pubmed: 20836077
Front Immunol. 2013 Aug 01;4:226
pubmed: 23914191
Biochem Pharmacol. 2010 Sep 15;80(6):867-73
pubmed: 20438716
Oncology. 2007;72(1-2):69-74
pubmed: 18004079
Adv Drug Deliv Rev. 2010 Oct 30;62(13):1285-98
pubmed: 20654663
Mol Cancer Res. 2014 Apr;12(4):527-538
pubmed: 24515801
J Pharmacol Exp Ther. 2009 Feb;328(2):469-77
pubmed: 18981289
Mol Cell Biol. 2017 Aug 28;37(18):
pubmed: 28674186
Redox Biol. 2017 Aug;12:340-349
pubmed: 28288414
FASEB J. 2011 Jan;25(1):192-205
pubmed: 20847229
Circ Res. 2013 Apr 26;112(9):1234-43
pubmed: 23524588
Am J Transl Res. 2009;1(1):62-71
pubmed: 19966939
Cancer Res. 2008 Dec 1;68(23):9589-94
pubmed: 19047134
Cancer Lett. 2013 Oct 28;340(1):72-81
pubmed: 23851184
Biochim Biophys Acta Mol Cell Biol Lipids. 2017 May;1862(5):496-512
pubmed: 28111285
Acta Pharm Sin B. 2015 Mar;5(2):135-44
pubmed: 26579439
Oncotarget. 2016 Jan 12;7(2):1096-106
pubmed: 26701854
Hepatology. 2017 Mar;65(3):893-906
pubmed: 28102638
Cancer Res. 2011 Jul 1;71(13):4628-39
pubmed: 21565979
Mol Cancer Res. 2007 Oct;5(10):981-9
pubmed: 17951399
PLoS One. 2012;7(11):e50013
pubmed: 23166811
Oncogene. 2006 Aug 7;25(34):4725-43
pubmed: 16892086
Br J Cancer. 2010 Oct 12;103(8):1215-20
pubmed: 20842113
PLoS One. 2016 Feb 03;11(2):e0148433
pubmed: 26840408
Mol Cell Biol. 2004 Nov;24(22):9705-25
pubmed: 15509776
Cell. 2004 Feb 20;116(4):527-40
pubmed: 14980220
PLoS One. 2011;6(5):e20291
pubmed: 21629773
EMBO J. 2002 Jun 3;21(11):2672-81
pubmed: 12032080
J Steroid Biochem Mol Biol. 2011 Feb;123(3-5):91-100
pubmed: 21167281
Curr Opin Gastroenterol. 2015 Mar;31(2):159-65
pubmed: 25584736
Cancer Lett. 2015 Jan 28;356(2 Pt B):410-7
pubmed: 25304371
Biochem Pharmacol. 2014 Oct 15;91(4):483-9
pubmed: 25175738
Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11295-300
pubmed: 9326603
Biochem Pharmacol. 2011 Apr 1;81(7):910-6
pubmed: 21241664
Biochem Pharmacol. 2013 Apr 1;85(7):1007-17
pubmed: 23396089
Am J Physiol Gastrointest Liver Physiol. 2014 Jul 15;307(2):G205-18
pubmed: 24833708
Oncogene. 2006 May 18;25(21):2974-86
pubmed: 16434970
J Cancer Res Clin Oncol. 2012 Aug;138(8):1355-61
pubmed: 22484852
Hepatology. 2011 Mar;53(3):865-74
pubmed: 21319187
J Biol Chem. 2015 Mar 6;290(10):6507-15
pubmed: 25596928
Cancer Res. 2010 Sep 1;70(17):6824-36
pubmed: 20660371
Immunity. 2014 Jan 16;40(1):128-39
pubmed: 24412617
Virchows Arch. 2011 Aug;459(2):129-39
pubmed: 21713366
Cell Death Differ. 2005 Apr;12(4):395-404
pubmed: 15665816
Clin Transl Gastroenterol. 2017 Jun 29;8(6):e103
pubmed: 28662021
Clin Cancer Res. 2005 May 1;11(9):3558-66
pubmed: 15867260
Oncogene. 2010 Sep 2;29(35):4980-8
pubmed: 20562918

Auteurs

Ying Hu (Y)

Department of Medical Pathology and Laboratory Medicine, University of California, Davis Health System, Sacramento, California, USA.

Samuel W French (SW)

Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA.

Thinh Chau (T)

Department of Medical Pathology and Laboratory Medicine, University of California, Davis Health System, Sacramento, California, USA.

Hui-Xin Liu (HX)

Department of Medical Pathology and Laboratory Medicine, University of California, Davis Health System, Sacramento, California, USA.

Lili Sheng (L)

Department of Medical Pathology and Laboratory Medicine, University of California, Davis Health System, Sacramento, California, USA.

Fang Wei (F)

Department of Gastroenterology and Hepatology, First Municipal People's Hospital of Guangzhou, Guangzhou Medical College, Guangzhou, China.

Jesse Stondell (J)

Division of Gastroenterology, University of California, Davis Health System, Sacramento, California, USA.

Juan C Garcia (JC)

Division of Gastroenterology, University of California, Davis Health System, Sacramento, California, USA.

Yanlei Du (Y)

Department of Gastroenterology and Hepatology, First Municipal People's Hospital of Guangzhou, Guangzhou Medical College, Guangzhou, China.

Christopher L Bowlus (CL)

Division of Gastroenterology, University of California, Davis Health System, Sacramento, California, USA.

Yu-Jui Yvonne Wan (YY)

Department of Medical Pathology and Laboratory Medicine, University of California, Davis Health System, Sacramento, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH